Product Overview

Enclomiphene 50 mg is a pharmaceutical formulation that contains the active ingredient enclomiphene citrate, a selective estrogen receptor modulator (SERM) used primarily in the management of female infertility. The product is manufactured by HAB Pharmaceuticals & Research Ltd, a company recognized for its commitment to quality and compliance with international regulatory standards. Each strip contains five tablets, and the medication is available in pack sizes of 50, 100, or 200 tablets, allowing patients and clinicians to select the most appropriate supply for ongoing treatment cycles. Enclomiphene is classified under the category of female infertility therapies and is offered as a generic alternative to branded SERM products. The tablets are film‑coated for ease of swallowing and are packaged to maintain stability throughout the typical 6‑to‑15‑day delivery window. This overview provides a foundation for understanding how enclomiphene fits into modern reproductive medicine and why it is considered a reliable option for women seeking to improve ovulatory function.

What is Enclomiphene 50 mg?

Enclomiphene citrate belongs to a class of compounds known as selective estrogen receptor modulators, which interact with estrogen receptors in the hypothalamus and pituitary gland to modulate the release of gonadotropins. Unlike its stereoisomer zuclomiphene, enclomiphene exhibits a more favorable side‑effect profile and greater potency in stimulating ovulation in certain patient populations. The 50 mg strength represents a standard dose that clinicians may prescribe when initiating ovulation induction, particularly in women with polycystic ovary syndrome (PCOS) or anovulatory cycles. The medication is administered orally, and its pharmacodynamic action leads to an increase in follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) secretion, thereby promoting the development and release of mature oocytes from the ovary. Detailed chemical information about enclomiphene can be reviewed through authoritative sources such as the PubChem database or the U.S. Food and Drug Administration (FDA) label. Understanding the pharmacological basis of enclomiphene helps patients appreciate how the drug contributes to restored hormonal balance and improved fertility outcomes.

Uses and Benefits

The primary clinical use of Enclomiphene 50 mg is to induce ovulation in women who have difficulty conceiving due to irregular or absent menstrual cycles. By stimulating the hypothalamic‑pituitary‑gonadal axis, the drug enhances the secretion of FSH and LH, which are essential for follicular growth and subsequent ovulation. Clinical studies have demonstrated that enclomiphene can achieve ovulation rates comparable to traditional agents such as clomiphene citrate, while potentially reducing the incidence of certain adverse effects like visual disturbances and mood changes. In addition to its ovulation‑inducing properties, enclomiphene may be incorporated into assisted reproductive technologies (ART) protocols, including controlled ovarian hyperstimulation, to optimize the number of mature follicles available for retrieval. Patients often experience improved menstrual regularity, increased chances of pregnancy per cycle, and a lower risk of ovarian hyperstimulation syndrome (OHSS) when the medication is used according to evidence‑based regimens. The benefits of enclomiphene are further amplified when combined with lifestyle modifications, nutritional support, and close medical supervision, making it a versatile component of comprehensive infertility treatment plans.

How It Works

Enclomiphene functions as a partial agonist and antagonist at estrogen receptors located in the brain’s regulatory centers. When bound to these receptors, enclomiphene blocks the negative feedback that estrogen normally exerts on the hypothalamus, leading to an up‑regulation of gonadotropin‑releasing hormone (GnRH) pulses. This cascade stimulates the anterior pituitary to secrete increased amounts of FSH and LH, hormones that are pivotal for follicular maturation and ovulation. The drug’s selective binding profile ensures that estrogenic activity is enhanced in peripheral tissues while antagonizing estrogenic effects in the breast and endometrium, which may reduce the risk of estrogen‑related complications. Pharmacokinetic studies indicate that enclomiphene reaches peak plasma concentrations within a few hours after oral administration, and its metabolites persist for several days, providing a sustained hormonal stimulus. The overall mechanism underscores why enclomiphene is classified as a “fertility‑enhancing” agent rather than a direct ovulatory stimulant; it works by restoring the natural signaling pathways that govern egg development.

Dosage Guidelines

Dosage of Enclomiphene 50 mg must be individualized by a qualified healthcare professional based on the patient’s medical history, baseline hormonal profile, and response to prior therapies. Typical initiating regimens involve a daily oral intake of 50 mg for up to five consecutive days, beginning early in the menstrual cycle (often on day 3‑5). Subsequent cycles may adjust the dose or duration according to ovulation response, as documented through ultrasound monitoring or hormonal assays. It is essential that patients do not self‑administer the medication without medical oversight, as inappropriate dosing can lead to suboptimal ovulation or an increased likelihood of multiple gestations. The prescribing information emphasizes the importance of adhering to the recommended treatment schedule and avoiding prolonged use beyond the established cycle length. For detailed dosing recommendations, clinicians can consult the Drugs.com monograph or the product’s official prescribing label. Patients should always discuss any missed doses, dosage adjustments, or concerns about efficacy with their prescribing physician before making changes.

Side Effects

Like all pharmaceutical agents, Enclomiphene 50 mg may be associated with adverse effects, although many are mild and transient. Commonly reported side effects include hot flashes, abdominal discomfort, breast tenderness, and occasional visual disturbances such as blurred vision or phosphorescent spots. Less frequent but clinically significant events can involve ovarian hyperstimulation, ovarian cysts, and, rarely, thromboembolic phenomena. Patients are advised to monitor for signs of severe abdominal pain, rapid weight gain, or shortness of breath, which may indicate ovarian hyperstimulation syndrome and require immediate medical attention. The drug’s label also cautions against its use in individuals with a history of liver disease, uncontrolled thyroid disorders, or known hypersensitivity to enclomiphene or related compounds. Healthcare providers should review a patient’s complete medication list to avoid potential drug interactions, particularly with medications that affect hepatic enzyme activity. Documentation of side effects in a patient diary can facilitate early identification of patterns and support timely clinical decision‑making.

Warnings and Precautions

Enclomiphene 50 mg is contraindicated in pregnant or lactating women, as well as in patients with known ovarian cysts that are not related to infertility treatment. Prior to initiation, a thorough evaluation should include a pelvic exam, hormonal profiling, and assessment of hepatic function to ensure the patient’s suitability for therapy. Because the medication can stimulate multiple follicle development, clinicians must be vigilant for the possibility of multiple pregnancies and should counsel patients regarding the associated risks. Patients with a history of thromboembolic disorders, stroke, or coronary artery disease should discuss these conditions with their physician, as SERMs can theoretically increase clot formation risk. It is also recommended that concomitant use of other estrogen‑modulating agents be avoided unless explicitly directed by a healthcare professional. For comprehensive safety information, refer to the FDA prescribing information and consult a qualified reproductive endocrinologist. Adherence to these precautions helps maximize therapeutic benefit while minimizing potential harm.

Frequently Asked Questions

1. Question: What is the typical duration of an enclomiphene treatment cycle? Answer: A standard cycle usually involves taking 50 mg daily for up to five days early in the menstrual cycle; the exact length is determined by a physician based on ovulation response.
2. Question: Can enclomiphene be used alongside other fertility medications? Answer: Enclomiphene may be combined with gonadotropins or other ovulation agents under medical supervision, but mixing with similar SERMs is generally avoided to prevent overstimulation.
3. Question: How does enclomiphene differ from clomiphene citrate? Answer: Enclomiphene is the more active stereoisomer of clomiphene, offering comparable ovulation rates with a potentially lower incidence of certain side effects such as visual disturbances.
4. Question: Is a prescription required to purchase enclomiphene online? Answer: Yes, enclomiphene is a prescription‑only medication; legitimate online pharmacies require a valid physician’s order before dispensing the product.
5. Question: Where can I find more detailed scientific information about enclomiphene? Answer: Detailed pharmacology and clinical data are available through resources such as the PubChem, the FDA, and the MedlinePlus databases.

Related Products

• Tretoin 0.1% Gel (Tretinoin)
• Tretoin 0.025% Cream (Tretinoin)
• Tretoin 0.05% Cream (Tretinoin)
• Tretinex Cream (Tretinoin)
• Tretoin Cream (Tretinoin)
• Naltrexone 50 mg (Naltrexone)
• Methylprednisolone (Signapred 4 mg)
• Signapred 4 mg (Methylprednisolone)
• Griseofulvin 500 mg (Generic)
• Lamifil 250 Mg (Terbinafine)
• Fungicyte 150 (Fluconazole 150mg)
• Dermozole 500 mg (Griseofulvin)